Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - April 2016


It’s been a busy start to the year at Cyprotex. In February, we signed a strategic partnering deal with Cytocentrics to offer a full panel of single ion channel services to complement our existing electrophysiology capabilities. In March, we released our new Chemical and Cosmetics Testing Guide, and we launched an advanced 3D liver model for detecting DILI potential. In April, we published a peer-reviewed publication on our research in the field of mitochondrial toxicity and launched new GLP and OECD-compliant genotoxicity services. Throughout the year, we have been presenting our novel research at conferences such as SOT, BTS and the AAPS/ITC Drug Transporter Workshop.

Partnering Agreement with Cytocentrics - CiPA Ion Channel Panel
In early February, we signed a deal with Cytocentrics, giving us the ability to offer a full range of cardiac ion channel assays in accordance with the Comprehensive in vitro Proarrhythmia Assay (CiPA) Consortium's recommendations for clinically-relevant ion channels. Our lab in Watertown, Massachusetts will house two CytoPatch TM4 instruments - automated patch clamps that use quartz glass pipettes and are capable of gigaseal recordings.

Learn more
CiPA Recommended Assays
New Chemical and Cosmetics Testing Guide Now Available
The Cyprotex Chemical and Cosmetics Testing Guide joins our popular ADME, Mechanistic Toxicity and DDI Guides and is now available for free through our website. The guide is focused in the field of chemical (including agrichemicals and industrial chemicals) and cosmetics or personal care testing and covers an overview of the US and EU legislation/guidance, as well as chapters on Integrated Testing Approaches, Skin Testing, Ocular Testing, Mutagenicity/Genotoxicity Testing and Endocrine Disruption Testing. Visit to request your free copy.

Request a copy
Cosmetics and Chemical Regulatory Guidance
Advanced 3D Liver Models for Predicting Hepatotoxicity
Our advanced hepatotoxicity model that uses 3D microtissue spheroids provides critical insight into mechanistic causes of liver toxicity, which is one of the leading causes of late stage attrition and market withdrawal. These models are analysed using a confocal High Content Screening instrument (Thermo Scientific ArrayScan™ XTI).

Learn more
3D Microtissues for Hepatotoxicity
OECD-compliant GLP Genotoxicity Assays
We are excited to offer a suite of GLP genotoxicity assays to meet regulatory testing requirements. Available services include Ames Test (OECD 471), in vitro Micronucleus Test (OECD 487), and in vitro Chromosome Aberration (OECD 473) (coming soon). Genotoxicity testing is required under ICH S2 (R1), REACH, CLP, FIFRA/TSCA and others.

Learn more
GLP genotoxicity assays
New Peer-Reviewed Publication on Mitochondrial Toxicity
Our latest peer-reviewed publication provides an in-depth comparison of the Seahorse XFe Flux Analysis assay and the Glu/Gal assay for detection of mitochondrial toxicity in vitro. Free reprints are available.

Request a reprint
Mitochondrial toxicity and mito-stress

New Research now available for Download

From SOT

  1. Scientific Workshop: A Novel High-Throughput In Vitro and Multivariate Spike Train Analysis Platform for Drug Neurotoxicity and Method of Action
  2. Poster Presentation: Human Stem Cell-Derived Neurons for Neurotoxicity Functional Screens
  3. Poster Presentation: Using the Short Time Exposure (STE) and Eye Irritation Test (EIT) for Full GHS Categorization of Ocular Irritation
  4. Poster Presentation: Detection of Drug Cholestatic Potential Using
    Confocal High Content Screening in HepaRG and Human Liver Microtissues
  5. Poster Presentation: Development of a Multiplatform Assay Using High Content Screening and Microelectrode Array to Assess Cardio, Neuro, and Hepato-Toxicity in a Group of Antipsychotic Drugs
  6. Poster Presentation: Confocal High Content Screening of Cardiac Microtissues for the Improved Prediction of Drug Induced Structural Cardiotoxicity
  7. Poster Presentation: A High Throughput High Content Screen for the Detection of Androgen Receptor Modulators

From BTS

  1. Oral Presentation: Development of 3D Cardiac and Hepatic Microtissue Models for the Improved Prediction of Clinical Cardio- and Hepatotoxicity
  2. Poster Presentation: The Combination of Measuring Oxygen Consumption and Extracellular Acidification with the Glu/Gal Assay Improves the Detection of Mitochondrial Toxicants
  3. Poster Presentation: The Potential of hLiMTs and HepaRG Spheroids to Improve the In Vitro Prediction of Drug-Induced Liver Injury (DILI) using a Repeat Dose High Content Screening (HCS) Approach

From AAPS/ITC/FDA Joint Workshop

  1. Poster Presentation: Further Investigation of the Impact of Inhibitor Pre-Incubation on Human OATP1B1, OAT3, OCT2 and MATE1 Transporter In Vitro Inhibitor Potencies
Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.